Purchased royalties on Pharvaris' deucrictibant in Phase 3 development for hereditary angioedema. FDA granted approvals for Bristol Myers Squibb's Cobenfy (formerly KarXT) for schizophrenia, Johnson ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback